Tempus AI to acquire Ambry Genetics
Nov. 5, 2024—Tempus AI announced it has entered into an agreement to acquire Ambry Genetics.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA clears QIAstat-Dx meningitis/encephalitis panel
Nov. 4, 2024—Qiagen announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis panel for clinical use.
Pillar gets CPT code for FDA-approved OncoReveal CDx kit
Oct. 24, 2024—Pillar Biosciences has announced it has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit.
Astellas Vylox, Roche Ventana CDx approved for gastric cancer
Oct. 22, 2024—The FDA has approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2 positive, as determined by an FDA-approved test.
Qiagen white paper compares literature mining tool scores
Oct. 18, 2024—Qiagen published a white paper, titled “NIH Study Finds HGMD Professional Demonstrates a 126% Higher Precision Score than AI-derived Databases,” that discusses expert curation tools that help identify relevant literature for variant classification and the findings of a study conducted by investigators at the National Human Genome Research Institute.
Bio-Rad expands External Quality Assurance Services program
Oct. 17, 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program.
Pillar expands commercial partnership with Illumina
Oct. 16, 2024—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina.
NeoGenomics launches AML Express NGS assay
Oct. 9, 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia.
CAP files amicus brief in LDT lawsuits
Oct. 8, 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al.
Qiagen launches QIAcuityDx dPCR system for oncology testing
Oct. 7, 2024—Qiagen announced the launch of the QIAcuityDx digital PCR system, an IVD medical device that integrates partitioning, thermocycling, and imaging into a streamlined five-plex workflow in a single instrument.